Developmental neuroscience

Okayama University Research: Dead Brain Cells can be Regenerated After Traumatic Injury

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Medical terminology, Neuron, Brain, Stem cells, Biology, Developmental neuroscience, Endogenous regeneration

OKAYAMA, Japan, Jan. 14, 2020 /PRNewswire/ --In a recent study published in Scientific Reports researchers at Okayama University describe the development of a method to generate neurons from other types of cells to compensate for brain cells lost during injury.

Key Points: 
  • OKAYAMA, Japan, Jan. 14, 2020 /PRNewswire/ --In a recent study published in Scientific Reports researchers at Okayama University describe the development of a method to generate neurons from other types of cells to compensate for brain cells lost during injury.
  • A stroke is a debilitating neurological condition that arises when there is deprivation of blood to brain cells.
  • Replacing dead neurons is therefore an ideal but very difficult strategy to regain loss of brain function.
  • Now, researchers at Okayama University have now developed a method of converting non-neuronal cells in the brain into neurons for this purpose.

Okayama University Research: Dead Brain Cells can be Regenerated After Traumatic Injury

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Medical terminology, Neuron, Brain, Stem cells, Biology, Developmental neuroscience, Endogenous regeneration

OKAYAMA, Japan, Jan. 14, 2020 /PRNewswire/ --In a recent study published in Scientific Reports researchers at Okayama University describe the development of a method to generate neurons from other types of cells to compensate for brain cells lost during injury.

Key Points: 
  • OKAYAMA, Japan, Jan. 14, 2020 /PRNewswire/ --In a recent study published in Scientific Reports researchers at Okayama University describe the development of a method to generate neurons from other types of cells to compensate for brain cells lost during injury.
  • A stroke is a debilitating neurological condition that arises when there is deprivation of blood to brain cells.
  • Replacing dead neurons is therefore an ideal but very difficult strategy to regain loss of brain function.
  • Now, researchers at Okayama University have now developed a method of converting non-neuronal cells in the brain into neurons for this purpose.

Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis

Retrieved on: 
Wednesday, January 8, 2020
Organ systems, Psychiatry, Nervous system, Psychiatric diagnosis, Neurological disorders, Learning disabilities, Developmental neuroscience, Autism, Rett syndrome, Neurodevelopmental disorder, Rett, Autism spectrum

10,507,196 to support Anavexs leading drug candidate, ANAVEX2-73 (blarcamesine) for the treatment of neurodevelopmental disorders including Rett syndrome, and multiple sclerosis.

Key Points: 
  • 10,507,196 to support Anavexs leading drug candidate, ANAVEX2-73 (blarcamesine) for the treatment of neurodevelopmental disorders including Rett syndrome, and multiple sclerosis.
  • It covers methods of treatment for neurodevelopmental disorders including Rett syndrome, autism spectrum disorder, Angelman syndrome, and cerebral palsy, among others, and also treatment for multiple sclerosis, using ANAVEX2-73 (blarcamesine).
  • Phase 2 Rett syndrome study1 and the AVATAR Rett syndrome study2, with the international EXCELLENCE Rett syndrome study of ANAVEX2-73 (blarcamesine) in pediatric patients scheduled to initiate early 2020.
  • The 196 patent adds important coverage for ANAVEX2-73 (blarcamesine) treatments for Rett syndrome and multiple sclerosis.

Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

Retrieved on: 
Monday, December 9, 2019
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Organ systems, Health, Neurological disorders, Nervous system, Autism, Learning disabilities, Psychiatric diagnosis, Developmental neuroscience, Rett, Neurodevelopmental disorder, Blinded experiment

Newron is initiating procedures for the Type A meeting with the FDA and will provide an update to the markets as soon as possible.

Key Points: 
  • Newron is initiating procedures for the Type A meeting with the FDA and will provide an update to the markets as soon as possible.
  • The type A meeting is expected to occur within thirty days of FDAs receipt of the meeting request and meeting package.
  • Newron will provide an update on the timing of the final unblinding and report of results of the STARS study for sarizotan after receipt of the FDAs final meeting minutes, which typically become available within thirty days after the type A meeting.
  • Rett syndrome is a severe neurodevelopmental disorder primarily affecting females, with an estimated prevalence of one in 10,000 females.

Global autism spectrum disorder therapeutics market is expected to grow with a CAGR of 4.4% over the forecast period from 2019-2025

Retrieved on: 
Wednesday, November 27, 2019
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Autism, Pervasive developmental disorders, Organ systems, Learning disabilities, Autism spectrum, Developmental neuroscience, Spectrum disorder, Evdokia Anagnostou

The report on the global autism spectrum disorder therapeutics market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • The report on the global autism spectrum disorder therapeutics market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global autism spectrum disorder therapeutics market to grow with a CAGR of 4.4% over the forecast period from 2019-2025.
  • The study on autism spectrum disorder therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on autism spectrum disorder therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global autism spectrum disorder therapeutics market over the period of 2017 to 2025.

Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Tuesday, November 26, 2019
Biotechnology, General Health, Health, Organ systems, Nervous system, Medical specialties, Developmental neuroscience, Neurodevelopmental disorder, Parkinson's disease

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY.

Key Points: 
  • Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY.
  • Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases.
  • The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005245/en/

Autism Spectrum Disorder (ASD) Fever Effect Pilot Study Completed

Retrieved on: 
Monday, November 18, 2019
Psychiatry, Abnormal psychology, Psychiatric diagnosis, Neuroscience, Pervasive developmental disorders, Developmental neuroscience, Developmental psychology, Autism, Autism therapies, Epidemiology of autism

(AVACEN) announced that its sponsored and independently conducted 12-family double blinded, double placebo-controlled, multi-phase (6 weeks per phase) pilot study of ASD children ages 4-17* has been completed.

Key Points: 
  • (AVACEN) announced that its sponsored and independently conducted 12-family double blinded, double placebo-controlled, multi-phase (6 weeks per phase) pilot study of ASD children ages 4-17* has been completed.
  • The Fielding Graduate University IRB approved study is entitled: "TheFever Effect: Do kids with autism do better when they use a device to warm their blood?
  • Effects of a six-week AVACEN Treatment Method on Autism Spectrum Disorder".
  • Unraveling the "fever effect" could lead to innovative ways to improve the lives of individuals affected by ASD.

New Therapy Center Designed for Children with Autism Opens in Rochester

Retrieved on: 
Tuesday, November 12, 2019
Psychiatry, Psychiatric diagnosis, Autism, Abnormal psychology, Health, Autism spectrum, Developmental neuroscience, Developmental psychology, Global perceptions of autism, Outline of autism

ROCHESTER, Minn., Nov. 12, 2019 /PRNewswire/ --Caravel Autism Health has opened the doors to a new center specifically designed to serve children with autism in the Rochester area.

Key Points: 
  • ROCHESTER, Minn., Nov. 12, 2019 /PRNewswire/ --Caravel Autism Health has opened the doors to a new center specifically designed to serve children with autism in the Rochester area.
  • Caravel Autism Health specialists offer two primary services: diagnosis and individualized autism treatment.
  • With the opening of the new center at 1470 Industrial Drive NW, Caravel Autism Health now offers a full array of diagnostic, in-home therapy and center-based therapy to children of all ages.
  • Caravel's team of autism health experts specializes in the evaluation, diagnosis and treatment of children on the autism spectrum.

Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase

Retrieved on: 
Friday, October 11, 2019
Mental health, Health, Clinical trials, Pharmaceutical, Biotechnology, Health, Medical specialties, Medicine, Developmental neuroscience, Neurodevelopmental disorder, Parkinson's disease

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.

Key Points: 
  • Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.
  • Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases.
  • The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20191011005018/en/

Young Man on the Autism Spectrum Pursues and Wins Coveted Internship with Congresswoman

Retrieved on: 
Tuesday, September 17, 2019
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Organ systems, Autism spectrum, Developmental neuroscience, Developmental psychology, Autism

During the tour Matsui and Task discussed the challenges of autistic and neuro-diverse young adults, especially as it relates to finding and retaining employment.

Key Points: 
  • During the tour Matsui and Task discussed the challenges of autistic and neuro-diverse young adults, especially as it relates to finding and retaining employment.
  • The next day he sent his resume to the congresswoman, secured an interview and was awarded an internship on the spot.
  • 50,000 students on the autism spectrum graduate from high school each year in the US.
  • MERISTEM, located outside of Sacramento, helps transition young adults on the autism spectrum to independent living, including college and career success.